Cardiology

Trials, guidelines and practice across cardiovascular medicine.

Cumulative TyG-BRI predicts incident cardiovascular disease in CHARLS cohort

Cumulative TyG-BRI was linked to higher incident cardiovascular disease risk in Chinese adults, with the strongest signal in the top exposure quartile.

By Dr. Aishwarya N., MBBS · Nov 5, 2026 · 5 min read

Cardiology·Nature

Sleep Impairment Linked to Higher Predicted Cardiovascular Risk and Atherosclerosis

NHANES analysis and mouse experiments link sleep impairment to higher predicted cardiovascular and heart failure risk and greater…

Nov 5, 2026

Cardiology·Nature

Glycemic and renal burden predicts cardiovascular disease risk in HRS cohort

Repeated glycemic and renal abnormalities were linked to higher incident cardiovascular disease risk in the Health and Retirement…

Nov 5, 2026

Cardiology·JACC

Proteomic Cardiovascular Risk Signatures in Asian Patients With Type 2 Diabetes

JACC examines novel proteomic signatures for cardiovascular risk prediction in Asian patients with type 2 diabetes, a group…

Nov 5, 2026

Cardiology·BMJ Open

AHA 2025 Heart Disease and Stroke Statistics Update expands global data

The 2025 AHA statistical update compiles current US and global cardiovascular data, with expanded equity focus and nearly…

Nov 5, 2026

Cardiology·JACC

Plasma Proteins Linked to Incident MI in Asians With Type 2 Diabetes

JACC: Asia abstract examines plasma proteins associated with incident acute myocardial infarction in Asians with type 2 diabetes.

Nov 5, 2026

Cardiology·JACC

LIPSIA-STRATEGY Trial Tests Angiography-Derived vs Wire-Based FFR

The randomized LIPSIA-STRATEGY trial compares angiography-derived and wire-based fractional flow reserve to guide revascularization decisions.

Nov 5, 2026

Cardiology·IN News

Terumo India and SMS Jaipur Launch Bifurcation PCI Training Program

Terumo India Skill Lab and SMS Jaipur will train young cardiologists in bifurcation PCI through simulation, case discussions…

Nov 5, 2026

Cardiology·DailyMed

Telmisartan and Hydrochlorothiazide Label Tightens Fetal and Renal Warnings

DailyMed label update for telmisartan and hydrochlorothiazide reinforces fetal toxicity, renal monitoring, dosing limits, and key drug interactions.

Nov 5, 2026

Cardiology·medRxiv

Fibromuscular Dysplasia Seen in 1 in 5 Women With Type A Dissection

A single-center preprint found fibromuscular dysplasia in 9% of acute type A aortic dissection cases and 19% of…

Nov 5, 2026

Cardiology

Trials, guidelines and practice across cardiovascular medicine.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.